
Regulatory
Latest Content

Pharmaceutical Executive Daily: Rethinking Workforce Development

Roundup: Biopharma Funding Rounds Advance Clinical Development of Novel Therapy and Treatment Solutions

Pharma Collaborations Focused on Advancing Antibody-Drug Conjugates and Delivering Treatments for Autoimmune Diseases

Assessing the Access Landscape

Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit

Shorts









Podcasts
Videos
All News

Biotech funding surges as companies like Pelage, Kardigan, and Kailera secure millions to innovate treatments for hair loss, obesity, and cardiovascular diseases.

The biopharmaceutical sector sees major acquisitions, enhancing capabilities in RNA therapies and rare diseases, with key players like BioCryst and Bristol Myers Squibb leading the charge.

A Harvard Business School Healthcare Alumni Association Q&A with Jennifer McCollum, CEO of Catalyst.

Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term biotech priorities depends on partnering.

In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.

Johnson & Johnson plans to separate its orthopaedics business, creating DePuy Synthes, to enhance focus, innovation, and value for stakeholders.

Nabla Bio and Takeda enhance their partnership to revolutionize AI-driven protein therapeutics, aiming for groundbreaking advancements in drug development.

Hunter Smith, CFO of Rhythm Pharmaceuticals, explains that in biotech, success often brings greater capital demands before profitability, requiring CFOs to balance continuous fundraising with careful management.

In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.

Pharmaceutical companies embrace direct-to-consumer sales and price cuts amid tariff changes and Trump's push for lower drug costs in the US.

Excellergy secures $70 million to advance innovative trifunctional ECRIs, aiming to redefine allergy treatment and improve patient outcomes.

In discussing the evolving role of biotech CFOs, Hunter Smith,CFO of Rhythm Pharmaceuticals, emphasized that today’s finance leaders must act as the “voice of the investor,” ensuring disciplined capital allocation and long-term value creation.

Ypsomed invests $250 million in a new U.S. manufacturing facility, enhancing local supply and creating jobs in Holly Springs, North Carolina.

In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.

The company’s CEO will reportedly joining the President to announce the deal.